Ustekinumab for fistulising perianal Crohn&apos;s disease: a randomised placebo-controlled trial from the GETAID

Inflammatory Bowel Disease

Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

Lancet Gastroenterol Hepatol

Jairath V, Kierkuś J, Duvall GA, Danese S, Sands BE, Ratiu-Duma B, Singh R, Levine P, Barkay H, Gross N, Abrams K, Reinisch W

doi: 10.1016/S2468-1253(26)00119-6

Inflammatory Bowel Disease

Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial

Lancet Gastroenterol Hepatol

Pigneur B, Martinez-Vinson C, Bourmaud A, Dabadie A, Duclaux-Loras R, Hugot JP, Roman C, Dumant C, Spyckerelle C, Guinard-Samuel V, Willot S, Dupont C, Breton A, Caron N, Chaillou E, Rebouissoux L, Bertrand V, Triolo V, Pages J, Djeddi D, Bonneton M, Uhlen S, Catteau N, Coopman S, Lepage P, Viala J, Ruemmele FM

doi: 10.1016/S2468-1253(25)00262-6

Inflammatory Bowel Disease

Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial

J Crohns Colitis

Raine T, Danese S, Schreiber S, Gao X, Hanauer S, Torres J, Cunneen C, Kligys K, Huang X, Garrison A, Neimark E, Anschutz T, Crowley J, Cross RK

doi: 10.1093/ecco-jcc/jjag104

Gastritis

Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial

Lancet Gastroenterol Hepatol

Gonsalves NP, Dellon ES, Kliewer KL, Shoda T, Yearout R, Aceves SS, Arva NC, Besse JA, Caldwell JM, Chehade M, Coleman A, Collins MH, Anvari S, Falk GW, Gupta SK, Hiremath G, Katzka DA, Khoury P, Leung J, Menard-Katcher C, Menard-Katcher P, Peterson KA, Pletneva MA, Spergel AKR, Spergel JM, Vaysman T, Wechsler JB, Wright BL, Yang GY, Zhang X, Zhou M, Bansal A, Raphael BP, Radwan A, Maloney J, Martin A, Deniz Y, Furuta GT, Martin LJ, Rothenberg ME, Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Investigators

doi: 10.1016/S2468-1253(26)00116-0

Inflammatory Bowel Disease

Magnetic resonance imaging-based simplified MaRIA scores are associated with future surgery in Crohn's disease, but modest correlation with ileo-colonoscopic inflammation limits their utility in clinical trials: results from the PROFILE trial

J Crohns Colitis

Bhandari M, Sharip MT, Noor NM, Khwaja S, Paverd H, De Paepe KN, Godfrey E, Hickman K, Patel KV, Subramanian S, Raine T, Lee JC, Kennedy NA, Upponi S, Parkes M, PROFILE Study Group

doi: 10.1093/ecco-jcc/jjag056

Further Publications

Comparative efficacy and safety of risankizumab versus ustekinumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis

Minerva Gastroenterol (Torino)

Moon S, Choi YJ, Shin S

doi: 10.23736/S2724-5985.26.04084-2

Inflammatory Bowel Disease

Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn's Disease: Opportunities and Challenges

Inflamm Bowel Dis

Jairath V, Adsul S, Allocca M, Danese S, Dubinsky MC, de Oliveira MF, Ma C, Kucharzik T, Novak KL, Panaccione R, Bautista IR, Sands BE, Taylor SA, Wilkens R, Maaser C

doi: 10.1093/ibd/izaf196

Inflammatory Bowel Disease

Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg

J Crohns Colitis

De Greef E, Turner D, Kierkuś J, Korczowski B, Meglicka M, Cohen SA, Hyams JS, Griffiths AM, Rosh JR, Strauss R, Van Limbergen E, Adedokun OJ, Kim L, Volger S, UNITI Jr study Group

doi: 10.1093/ecco-jcc/jjag011

Inflammatory Bowel Disease

Real-World Effectiveness of Upadacitinib for Perianal Crohn's Disease: A Multi-Center Retrospective Study

Clin Gastroenterol Hepatol

Devi J, Patel A, Quraishi B, Dev B, Tan T, Kline M, Chowla N, Ramesh PR, Ballard DH, Huang L, Jaiprada F, Samaan S, Stone M, Khan A, Seeraj AA, Alanazi S, Xu A, Maas L, Jajoo A, Parian A, Altinmakas E, Ehman EC, Davenport MS, Li S, Chithriki M, Shukla R, McCurdy J, Yarur AJ, Bishu S, Johnson AM, Benjamin M, Dulaney D, Serre-Yu W, Deepak P

doi: 10.1016/j.cgh.2026.05.003

Gastroenterology

Ustekinumab for fistulising perianal Crohn's disease: a randomised placebo-controlled trial from the GETAID

Related content

Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial

Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial

Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial

Magnetic resonance imaging-based simplified MaRIA scores are associated with future surgery in Crohn's disease, but modest correlation with ileo-colonoscopic inflammation limits their utility in clinical trials: results from the PROFILE trial

Comparative efficacy and safety of risankizumab versus ustekinumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis

Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn's Disease: Opportunities and Challenges

Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg

Real-World Effectiveness of Upadacitinib for Perianal Crohn's Disease: A Multi-Center Retrospective Study